|
[1] 王鲁建,孙丽梅. 乳腺癌中AKT激活与耐药蛋白表达相关性. 中国组织化学与细胞化学杂志,2012, 21(4): 401-405. Wang L J, Sun L M. AKT activation and breast cancer resistance protein expression correlated. Chinese Journal of Histochemistry and Cytochemistry, 2012, 21(4): 401-405.
[2] 刘伦华,楼丽广. 丝/苏氨酸蛋白激酶Akt及其靶向药物研究进展. 中国药理学通报,2006, 22(1): 1-4. Liu L H, Lou L G. Advance in drug targeting serine/threonine protein kinase Akt. Chinese Phamacological Bulletin, 2006, 22(1): 1-4.
[3] Yu Z B, Bai L, Qian P, et al. Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by down regulating activation of Erk1/2, Akt apart from STAT3. Cell Biol Int, 2009, 33(9): 995-1001.
[4] Gardai S J, Hildeman D A, Frankel S K, et al. Phosphorylation of Bax Ser (184) by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem, 2004, 279(20): 21085-21095.
[5] Linseman D A, Butts B D, Precht T A, et al. Glycogen synthase kinase-3 beta phosphorylates bax and promotes its mitochondrial localziation during neuronal apoptosis. J Neurosci, 2004, 24(44): 9993-10002.
[6] Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell, 1996, 87(4): 619-628.
[7] 王维,张琍. PI3K/Ak信号转导通路的研究进展. 现代医药卫生,2010, 26(7): 1051-1052. Wang W, Zhang L. Progress pathway PI3K/Akt signal transduction. Modern Medicine & Health, 2010, 26(7): 1051-1052.
[8] Restuccia D F, Hemmings B A. Blocking Akt-ivity. Science, 2009, 325(5944): 1083-1084.
[9] 张超,章雄文,丁健. Akt-mTOR的互动与癌症的发生. 生命科学,2007, 19(1): 21-26. Zhang C, Zhang X W, Ding J. Akt-mTOR interplaying and carcinogenesis. Chinese Bulletin of Life Sciences, 2007, 19(1): 21-26.
[10] Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci, 2009, 34(3): 115-127.
[11] Gills J J, Dennis P A. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Emerg Dr, 2004, 13(7): 787-797.
[12] Scheid M P, Woodgett J R. Unravelling the activation mechanisms of protein kinase B/Akt. Febs Lett, 2003, 546(1): 108-112.
[13] Mayo L D, Donner D B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci, 2002, 27(9): 462-467.
[14] Ye B, Jiang L L, Xu H T, et al. Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopath Ph, 2012, 25(3): 627-636.
[15] Hovelmann S, Beckers T L, Schmidt M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Brit J Cancer, 2004, 90(12): 2370-2377.
[16] Yu L, Alva A, Su H, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science, 2004, 304(5676): 1500-1502.
[17] Ren S, Gao C, Zhang L, et al. PI3K inhibitors changed the p53-induced response of Saos-2 cells from growth arrest to apoptosis. Biochem Bioph Res Co, 2003, 308(1): 120-125.
[18] Yang W L, Wang J, Chan C H, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 2009, 325(5944): 1134-1138.
[19] 梁若飞,刘艳辉. PI3K/Akt/mTOR信号通路靶向治疗胶质细胞瘤研究进展. 中华神经外科疾病研究杂志,2013, 12(4): 375-377. Liang R F, Liu Y H. Research progress of targeting PI3K/Akt/mTOR signaling pathway on glioma therapy. Chinese Journal of Department of Neurosurgery Disease Research, 2013, 12(4): 375-377.
[20] Kubota N, Okada S, Inada T, et al. Wortmanin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation. Cancer Lett, 2000, 161(2): 141-147.
[21] Hu L, Zaloudek C, Mills G B, et al. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3- kinase inhibitor (LY294002). Clin Cancer Res, 2000, 6(3): 880-886.
[22] Cheng Y, Zhang y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of AKT, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther, 2012, 11(1): 154-164.
[23] Schnetzke U, Fischer M, Kuhn A K, et al. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol, 2013, 139(4): 605-615.
[24] Luo J, Manning, B D, Cantley L C. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell, 2003, 4(4): 257-262.
[25] 邢长英,归绥琪. SOCS3作用机制与妇产科研究进展. 生殖与避孕,2007, 27(4): 287-291. Xing C Y, Gui S Q. Research progress of SOCS3's mechanisms and obstetrics and gynecology. Journal of Reproduction & Contraception, 2007, 27(4): 287-291.
[26] 牛丽娜,陈显久. SOCS3结构和作用机制研究进展. 现代肿瘤医学,2014, 22(11): 2757-2760. Niu L N, Chen X J. Research progress of SOCS3 on its structure and mechanisms. Journal of Modern Oncology, 2014, 22(11): 2757-2760.
[27] 秦伟. 细胞因子信号转导抑制蛋白3与骨髓增殖性肿瘤关系的研究进展. 中国实验血液学杂志,2010, 18(4): 1101-1104. Qin W. Research advances on relationship suppressor of cytokine signaling and myeloproliferative neoplasms. Journal of Experimental Hematology, 2010, 18(4): 1101-1104.
[28] 薛帆,崔雪薇,张春东. 细胞因子信号传导抑制蛋白-3(SOCS-3)作用的研究进展. 中国当代医药,2011, 18(4): 18-19. Xue F, Cui X W, Zhang C D. Research progress of SOCS3 on its function. Journal of China Modern Medicine, 2011, 18(4): 18-19.
[29] 林娜,姚晓光,李南方. 细胞因子信号转导抑制因子3的研究进展. 中国医学科学院学报,2012, 34(2): 178-182. Lin N, Yao X G, Li N F. Research advances in suppressor of cytokine signaling 3. Acta Academiae Medicinae Sinicae, 2012, 34(2): 178-182.
[30] 李晟,王大文,朱诗建,等. 细胞因子信号传导抑制蛋白-3在前列腺癌中作用的研究进展. 临床泌尿外科杂志, 2014, 29(9): 845-847. Li S, Wang D W, Zhu S J, et al. Research progress of suppressor of cytokine signaling-3 in prostate cancer. The Journal of Clinical Department of Urology, 2014,29(9): 845-847.
[31] Danielle L, Douglasj K R, Ilton H. SOCS proteins: negative regulators of cytokine signaling. Stem Cells, 2001, 19(5): 378-387.
[32] Liu R Y, Zeng Y Y, Zhe Z. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol, 2014, 44(5): 1643-1651.
[33] Wang S W, Sun Y M. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (review). Int J Oncol, 2014, 44(4): 1032-1040.
[34] Yang G L, Ma F, Zhong M X. Interleukin-11 induces the expression of matrix metalloproteinase 13 in gastric cancer SCH cells partly via the PI3K-AKT and JAK-STAT3 pathways. Mol Med Rep, 2014, 9(4): 1371-1375.
[35] Lo H W, Cao X, Zhu H, et al. Constitutively activated STAT3 frequently with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to lressa and alkylators. Clin Cancer Res, 2008, 14(19): 6042-6054.
[36] Wu K, Chang Q S, Lu Y J, et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget, 2013, 4(12): 2430-2437.
[37] Sharma D, Saxena N K, Vertino P M, et al. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr-related Cancer, 2006, 13(2): 629-640.
[38] Saxena N K, Titus M A, Ding X, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regu-lated kinase (Erk) and Akt phosphorylation. Faseb J, 2004, 18(11): 1612-1614.
[39] Bjorbaek C, El-Haschimi K, Frantz J D, et al. The role of SOCS-3 in leptin signaling and leptin resistance. J of Biol Chem, 1999, 274(42): 30059-30065.
[40] Bjorbaek C, Elmquist J K, Frantz J D, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell, 1998, 1(4): 619-625.
[41] Sharm D, Wang J, Ping P, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 2010, 52(5): 1713-1722.
[42] Francipane M G, Eterno V, Spina V, et al. Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res, 2009, 69(15): 6141-6148.
[43] Frobose H, Ronn S G, Heding P E, et al. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol, 2006, 20(7): 1587-1596.
[44] Yajima T, Murofushi Y, Zhou H B, et al. Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias. Circulation, 2011, 124(24): 2690-2701.
[45] Nam K W, Chae S, Song H Y, et al. The role of wogonin in controlling SOCS3 expression in neuronal cells. Biochem Bioph Res Co, 2014, 450(4): 1518-1524.
[46] 林芳,崔强,钱程. 携带 SOCS-3 基因的溶瘤腺病毒的构建及体外抗肿瘤活性的研究. 浙江理工大学学报,2008, 25(1): 106-112. Lin F, Cui Q, Qian C. Construction and in vitro studies carried SOCS-3 oncolytic adenovirus gene antitumor activity. Journal of Zhejiang Sci-Tech University, 2008, 25(1): 106-112.
|
